Extended-release ranolazine: critical evaluation of its use in stable angina

Coronary heart disease is the major cause of morbidity and mortality throughout the world, and is responsible for approximately one of every six deaths in the US. Angina pectoris is a clinical syndrome characterized by discomfort, typically in the chest, neck, chin, or left arm, induced by physical...

Full description

Saved in:
Bibliographic Details
Published in:Vascular health and risk management 2011-01, Vol.7, p.535-539
Main Authors: Truffa, Adriano Am, Newby, L Kristin, Melloni, Chiara
Format: Article
Language:English
Subjects:
Acetanilides - adverse effects
Acetanilides - therapeutic use
angina
Angina pectoris
Angina, Stable - diagnosis
Angina, Stable - drug therapy
Angina, Stable - physiopathology
Angina, Stable - psychology
Animals
antianginal
Cardiovascular Agents - adverse effects
Cardiovascular Agents - therapeutic use
Cardiovascular disease
coronary heart disease
Delayed-Action Preparations
Health risk assessment
Humans
Piperazines - adverse effects
Piperazines - therapeutic use
Quality of Life
Ranolazine
Review
stable angina
treatment
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronary heart disease is the major cause of morbidity and mortality throughout the world, and is responsible for approximately one of every six deaths in the US. Angina pectoris is a clinical syndrome characterized by discomfort, typically in the chest, neck, chin, or left arm, induced by physical exertion, emotional stress, or cold, and relieved by rest or nitroglycerin. The main goals of treatment of stable angina pectoris are to improve quality of life by reducing the severity and/or frequency of symptoms, to increase functional capacity, and to improve prognosis. Ranolazine is a recently developed antianginal with unique methods of action. In this paper, we review the pharmacology of ranolazine, clinical trials supporting its approval for clinical use, and studies of its quality of life benefits. We conclude that ranolazine has been shown to be a reasonable and safe option for patients who have refractory ischemic symptoms despite the use of standard medications (for example, nitrates, beta-adrenergic receptor antagonists, and calcium channel antagonists) for treatment of anginal symptoms, and also provides a modestly improved quality of life.
ISSN:1178-2048
1176-6344
1178-2048
DOI:10.2147/VHRM.S15560